Citadel Advisors
YMAB

Citadel Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Citadel Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,100
Closed -$9.3K – 15435
2025
Q1 		$9.3K Buy
2,100
+1,200
+133% +$6.97K ﹤0.01% 13602
2024
Q4 		$7.05K Buy
900
+500
+125% +$6.09K ﹤0.01% 13760
2024
Q3 		$5.26K Buy
400
+100
+33% +$1.27K ﹤0.01% 13510
2024
Q2 		$3.62K Sell
300
-20,900
-99% -$282K ﹤0.01% 13573
2024
Q1 		$345K Buy
21,200
+18,900
+822% +$255K ﹤0.01% 9177
2023
Q4 		$15.7K Buy
+2,300
New +$13.3K ﹤0.01% 12825
2023
Q3 		– Sell
-1,600
Closed -$10.9K – 15256
2023
Q2 		$10.9K Buy
1,600
+1,200
+300% +$8.99K ﹤0.01% 13172
2023
Q1 		$2K Buy
+400
New +$1.63K ﹤0.01% 14221
2021
Q4 		– Sell
-11,100
Closed -$317K – 14908
2021
Q3 		$317K Buy
+11,100
New +$350K ﹤0.01% 10953

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's YMAB Position: Q3 2025 in Review

Citadel Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 207,642 shares — an estimated $936K sold.

Citadel Advisors first reported a position in YMAB in Q4 2019 and held it in 22 quarters. The position peaked at $5.92M in Q2 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Citadel Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 207,642 Y-mAbs Therapeutics shares in Q3 2025, an estimated $936K.
  • Citadel Advisors first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 22 quarters.
  • Citadel Advisors's Y-mAbs Therapeutics position peaked at $5.92M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.